202057-76-9
202057-76-9 結(jié)構(gòu)式
基本信息
中文別名
化合物 T11941 英文別名
FK778manitimus
2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-
2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
物理化學性質(zhì)
沸點489.4±45.0 °C(Predicted)
密度1.382±0.06 g/cm3(Predicted)
儲存條件-20°C儲存
溶解度DMSO: 250 mg/mL (811.00 mM)
酸度系數(shù)(pKa)5.23±0.50(Predicted)
形態(tài)Solid
顏色Light yellow to yellow
202057-76-9價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-101603 | 202057-76-9 Manitimus | 202057-76-9 | 1mg | 2000元 |
| 2026/06/05 | HY-101603 | 202057-76-9 Manitimus | 202057-76-9 | 5mg | 4000元 |
| 2026/06/05 | HY-101603 | Manitimus | 202057-76-9 | 10 mM * 1 mLin DMSO | 4400元 |
常見問題列表
生物活性
Manitimus 是一種 dehydroorotate dehydrogenase 的抑制劑，同時為有效的免疫抑制藥。體內(nèi)研究
In the Manitimus-treated rats, there is a dose-related, differential effect: mean survival is 15.7 days in group 4 (Manitimus 5 mg/kg), 19.1 days in group 5 (Manitimus 10 mg/kg) and 25.4 days in group 6 (Manitimus 20 mg/kg). Manitimus (15 mg/kg, p.o.) results in a significant decrease in neointimal area and percentage of stenosis versus the control rats, and diminishes the effect that CMV infection results in a significant increase in intimal and medial cross-sectional area and medial wall thickness of the vein grafts.